Gender |
Male |
3189 |
947 (29%) |
χ (3) = 68.2, p = 0.005 |
Female |
2570 |
1022 (39%) |
Age group |
01–14 |
437 |
96 (22%) |
|
15–24 |
1137 |
396 (34%) |
25–34 |
1180 |
473 (40%) |
35–44 |
827 |
298 (26%) |
45–54 |
732 |
227 (31%) |
55–64 |
819 |
282 (34.4%) |
65–100 |
627 |
197 (31.4%) |
Treatment history |
Previously Treated |
1024 |
461 (45%) |
χ (3) = 68, p-value = 0.05 |
Never Treated |
3922 |
1508 (38%) |
Disease type |
Pulmonary |
5290 |
1864 (35%) |
χ (3) = 68, p-value < 0.05 |
Extra Pulmonary |
469 |
105 (22%) |
Sample type |
Ascetic Fluid |
91 |
10 (11%) |
χ (36) = 259.6, p-value ≤ 0.05 |
BAL*
|
172 |
45 (26%) |
Bone |
20 |
2 (10%) |
CSF
**
|
44 |
2 (5%) |
Gastric Lavage |
68 |
5 (7%) |
Lymph Node |
10 |
3 (30%) |
Pericardial fluid |
26 |
3 (12%) |
Pleural Fluid |
172 |
26 (15%) |
Pus |
54 |
9 (17%) |
Sputum |
5033 |
1858 (37%) |
Synovial Fluid |
3 |
0 (0%) |
Tissue |
20 |
5 (25%) |
Urine |
46 |
1 (2%) |